infection. Multivariable regression analyses controlled for demographic variables and comorbidities.
RESULTS:
Of the 10,784 patients who underwent immediate prosthesis-based reconstruction, 5,516 (51%) filled antibiotic prescriptions. These patients were equally likely to develop an infection (OR 1.0 95%CI(0.85-1.18); p=0.98) or require explantation ); p=0.64) compared to those who did not. There was no difference in the likelihood of infection or explantation based on duration of antibiotics of 1-5 days (OR 0.85 95%CI(0.59-1.08); p=0.08), 6-10 days (OR 1.01 95%CI(0.90-1.14); p=0.84), or greater than 10 days 
METHODS:
Patients undergoing autologous breast reconstruction from August 2010-July 2016 were reviewed. Initiation of chemoprophylaxis changed from postoperative to preoperative in 2013, dividing subjects into two groups. Patient demographics, comorbidities, and complications were reviewed.
RESULTS:
A total of 196 patients (311 flaps) were included in the study (mean age 51.4, SD 4.9; mean BMI 26). A total of 105 patients (166 flaps) received preoperative enoxaparin 40mg while 91 patients (145 flaps) received postoperative chemoprophylaxis. A total of four patients required hematoma evacuation, overall incidence of 2.04%. No hematomas (0%) occurred in the preoperative chemoprophylaxis group (p=0.045). Six patients received blood transfusions; two in the preoperative group, and four in the postoperative group (1.9% vs 4.4%, p=0.419). There was a total of one flap failure and no documented VTE in all groups.
CONCLUSION:
This study demonstrates that preoperative chemoprophylaxis can safely be used in patients undergoing microvascular breast reconstruction. The higher rate of bleeding in the postoperative group may be related to the onset of action of enoxaparin of 4-6 hours, which allows for intraoperative hemostasis in the preoperative group while possibly potentiating postoperative oozing when administered postoperatively. 
